Researchers from Eastern Virginia Medical School Describe Findings in Life Sciences

A study published by CONRAD in Sexually Transmitted Diseases and summarized by LawRx.com found that in the case of the microbicide UC781, “Five safety/pharmacokinetic studies of UC781 are currently underway in women and men, all utilizing UC781 concentrations less than 1%, with twice-daily dosing in some studies, and all involving careful monitoring of exposed epithelium.”